Michael Mack教授在2025年纽约瓣膜会议上的演讲为心血管医学界提供了重要的学术指导和思考方向。他关于"早期TAVR不会显著改变指南，需要更强证据支持"的观点，体现了一位资深专家对循证医学原则的坚持和对患者安全的高度责任感。

Transcatheter aortic-valve replacement treats aortic stenosis by displacing and functionally replacing the native valve with a bioprosthetic valve delivered on a catheter through the femoral ...

The company will use the funds for a European feasibility study for its transcatheter device and for the launch of a ...

Transcatheter aortic-valve replacement (TAVR) has been increasingly used as an alternative to surgery for treating patients with severe, symptomatic aortic stenosis. 1,2 Randomized trials of both ...

Four complex heart surgeries were done without a single chest cut using TPVR Read ahead to know how this minimally invasive ...

Transcatheter aortic valve implantation (TAVI) is now an established treatment option for elderly patients with severe ...

RATES of permanent pacemaker implantation (PPI) exceed 20% in patients with aortic regurgitation (AR). A new retrospective ...

Scott Gottlieb, MD From the first early stages of its development, the prospect of transcatheter aortic valve replacement (TAVR) provoked two broad and competing fears: Regulatory safeguards would ...

Depending on procedure, the transfemoral, segment dominated the market in 2020, and this trend is expected to continue during ...